Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Aldesleukin + CISH-inactivated autologous TILs + Cyclophosphamide + Fludarabine |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Aldesleukin | Proleukin | IL-2|Interleukin-2|IL2 | Aldesleukin (IL-2) is a cytokine that potentially modulates antitumor immune response (NCI Drug Dictionary). | |
CISH-inactivated autologous TILs | Autologous CISH-inactivated TILs|CISH inactivated TIL | CISH-inactivated autologous TILs are patient-derived tumor infiltrating lymphocytes engineered to have disruption of cytokine-induced SH2 protein (CISH), which potentially results increased anti-tumor immune response (PMID: 36007524). | ||
Cyclophosphamide | Cytoxan | CPM | Chemotherapy - Alkylating 18 | Cytoxan (cyclophosphamide) is an alkylating agent, which inhibits DNA replication (NCI Drug Dictionary). Cytoxan (cyclophosphamide) is FDA approved in multiple hematological malignancies, breast cancer, neuroblastoma, ovarian cancer, and retinoblastoma (NCI Drug Dictionary). |
Fludarabine | Fludara | FAMP|Fludarabine phosphate | Flurdara (fludarabine) is converted to 2-fluoro-ara-ATP intracellularly, which potentially inhibits DNA polymerase alpha, ribonucleotide reductase and DNA primase, leading to decreased DNA synthesis and reduced tumor growth (NCI Drug Dictionary) |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04426669 | Phase Ib/II | Aldesleukin + CISH-inactivated autologous TILs + Cyclophosphamide + Fludarabine | A Study of Metastatic Gastrointestinal Cancers Treated With Tumor Infiltrating Lymphocytes in Which the Gene Encoding the Intracellular Immune Checkpoint CISH Is Inhibited Using CRISPR Genetic Engineering | Recruiting | USA | 0 |
NCT05566223 | Phase Ib/II | Aldesleukin + CISH-inactivated autologous TILs + Cyclophosphamide + Fludarabine Pembrolizumab | Phase 1/2 Study of CISH Inactivated TILs in the Treatment of NSCLC (CheckCell-2) | Not yet recruiting | USA | 0 |